Background/Objective: Our objective was to obtain follow-up pulmonary function testing and
| INTRODUCTION
A single course of antenatal steroids (AS) is the standard of care for women at risk for preterm delivery between 24 and 34 weeks of gestation, and significantly decreases mortality and respiratory distress syndrome (RDS). 1, 2 The optimal response occurs if it is given at least 24 h before but within 7 days of delivery, 1, 2 but this is often difficult to time. The efficacy and safety of repeat courses of AS remains a topic of debate. [3] [4] [5] [6] [7] [8] Randomized data show weekly courses of AS in preterm infants may improve lung function outcomes. 4, 5 A meta-analysis comparing a single to repeat courses of AS showed repeat courses decreased the occurrence and severity of neonatal lung disease, but in some trials there was a reduction in mean birth weight. 9 Therefore concern remains of possible harm after repeat AS therapy, particularly in terms of reduced growth (including lung growth) and long-term neurodevelopmental outcome. 10 Growth retardation and changes in lung structure have been shown in animal models after high dose AS therapy. 11, 12 We reported a single rescue course of AS versus placebo (given to pregnant women who remained pregnant ≥14 days after an initial course of AS) significantly increases respiratory compliance measured within 72 h of age and decreases oxygen need in their newborns. 13 These results provide a physiologic basis to the findings of a multicenter trial (n = 558 newborns) documenting significantly decreased composite morbidity and RDS without apparent increased short-term risk, in newborns of pregnant women randomized to a rescue course of AS versus placebo. 14 Although several large trials of weekly/repeat AS therapy have reported their growth and neurodevelopmental follow-up data, [7] [8] [9] there are insufficient data on the relative risks and benefits of a single rescue course of AS. Further, the effects of a rescue course of AS on pulmonary function and clinical respiratory outcomes in infants at 1-2 years of corrected age have not been evaluated.
The objective of the present study was to obtain follow-up pulmonary function testing and clinical respiratory outcomes, at 1-2 years of corrected age, in the original cohort of infants whose mothers were randomized to a single rescue course of AS versus placebo. We hypothesized those infants whose mothers received a rescue course of AS would have comparable pulmonary function and clinical respiratory outcomes to those whose mothers received placebo.
2 | METHODS
| Eligibility criteria
Inclusion criteria for the original randomized, placebo-controlled trial have been previously described. 13 Briefly, pregnant women 26 to <34
weeks' gestation, undelivered ≥14 days after their first course of AS, and at risk of preterm delivery were randomized to a single rescue course of 
| Study design
This is the respiratory follow-up of a randomized, double-blinded, placebo-controlled trial. Pregnant women assigned to the "rescue Tidal volume was calculated by digital integration of the flow signal as previously described. 18, 22 Briefly, a minimum of 12 flowvolume loops with inspiratory and expiratory volumes within 15%
were collected to estimate tidal volumes. As in the original randomized controlled trial (RCT), the statistical analyses were on intention-to-treat. In our original study, results were adjusted for gestational age at birth, twin gestation, maternal smoking history, rupture of membranes, and gestational diabetes, as these were the initial predictors of interest. 13 In the   FIGURE 1 Outline of randomization, treatment, and follow-up of study participants. A few patients in the rescue AS group and in the placebo group did not have PFT measurements because parents refused sedation or due to inability to meet the acceptance testing criteria. 13 to reject the null hypothesis with a type I error of 0.05 and a power of 80%. 13 For the current follow-up study (secondary outcomes), a post-hoc power analysis estimated that the study had 80% power (α = 0.05) to detect a 30% difference in Crs between groups.
| RESULTS
A total of 44 mothers with 56 babies were randomized to a rescue course of AS and 41 mothers with 57 babies to placebo. The first eight patients were recruited at Sacred Heart Hospital, with the remaining patients recruited at OHSU. Neonatal data were not available for one baby in the placebo group, resulting in 56 versus 56 babies available for analysis of the initial hospital stay. 13 In our original study, we reported no significant differences in maternal and infant characteristics or in survival between groups, except for more maternal smoking by history in the rescue compared to the placebo group (25% vs 5%, P < 0.05).
There were no significant differences in twin gestation (27% vs 39%), average birth weight (1806 vs 1830 g), or average gestational age at birth (31.9 vs 32.3 weeks) between the rescue and placebo groups. 13 As previously reported, 13 infants in the rescue group had a significantly increased Crs within 72 h of age and significantly fewer patients in the rescue group required ≥30% or ≥40% oxygen than in the placebo group (P < 0.05). There was no significant difference in infants that required surfactant (27% in the rescue vs 39% in the placebo group).
Three patients in the rescue and four patients in the placebo group developed bronchopulmonary dysplasia (BPD). There was one neonatal death and one post-neonatal death in the rescue group.
Thus, 110 survivors (54 randomized to rescue AS and 56 to placebo)
were eligible for assessment of clinical respiratory outcomes with respiratory questionnaires at 1-2 years of age. We obtained follow-up in 87% of these patients (Fig. 1) . Thirteen patients were ineligible for performance of PFTs due to physical location (follow-up PFTs could only be performed at OHSU) leaving 97 patients eligible for PFTs. We were able to perform follow-up PFTs in 77% of these patients (Fig. 1 ).
There was no significant difference in baseline demographics between the patients studied at follow-up and those who were not studied.
Infant characteristics including corrected age at study, length at study, weight, head circumference, race, or gender at the time of followup PFTs were comparable between groups. A positive family history of asthma was more common in the placebo group (3% vs 22%, P < 0.05) ( Table 1 ). The average weight in both groups was 10.6 kg and length was 78 cm in both groups. There was no significant difference in z-scores for length, weight, or head circumference 16 between the groups (Table 1) . (Fig. 1) . 13, 24 Table 2 shows the follow-up PFT data. There was no significant difference in tidal volume, total Crs or Crs/kg, and total FRC or FRC/kg between the groups. These differences remained not significant after accounting for the correlation between twins, and using mixed linear modeling to adjust for the potential confounders of: length at time of study, corrected age at study, and family history of asthma. Infants in the rescue AS group had a mean total FRC of 249.4 versus 246.2 mL in the placebo group (adjusted 95%CI for difference −15.45 to 38.20; P = 0.37) ( Table 2 ). Individual measurements of total FRC related to infant length at time of study are presented in Fig. 2 .
We were able to obtain clinical respiratory outcomes in 49 patients (91%) in the rescue AS group and 47 patients (84%) in the placebo group at 1-2 years of age. We demonstrated no significant differences between the rescue and placebo groups in episodes of wheezing, RSV infection, physician-diagnosed asthma, respiratory readmissions, and use of bronchodilators or other respiratory medications (inhaled and oral corticosteroids) ( Table 3 ). These differences remained not significant after accounting for the correlation between twins, and using GEE to adjust for the important confounding variables of corrected age at study and family history of asthma (Table 3) .
| DISCUSSION
This follow-up study demonstrates no difference in PFTs (tidal volume, respiratory compliance, or functional residual capacity), at 1-2 years of corrected age, in infants born to pregnant women randomized to a single rescue course of AS versus placebo. Clinical respiratory outcomes (assessed with a standardized respiratory questionnaire) also were not significantly different between the groups.
Our original study was a randomized, double-blind, placebocontrolled trial, however we acknowledge some limitations. Preterm delivery is difficult to predict, but 73.5% of our patients delivered at ≤34 weeks and 88% received the full course of study medication. 13 Our original study was powered to detect differences in pulmonary function tests at birth (primary outcome), thus assessment of followup PFTs and other clinical respiratory outcomes may need a larger sample size. We limited potential confounders such as maternal and delivery factors, postnatal growth, and environmental factors by using a randomized, placebo-controlled study design. Outcomes were assessed blinded to treatment group assignment, eliminating any possibility of expectation bias. The infants mean corrected age at testing was 18.8 months in the rescue versus 16.6 months in the placebo group; however, the median age and the infant length at testing were very similar between the groups, so it is unlikely that age confounded our results. Also, our follow-up PFTs/clinical respiratory outcomes were adjusted for the correlation between twins and possible confounding by corrected age at study, length at study, and family history of asthma. Finally, we did not include measurements of peripheral airway function. This will need to be included in future studies.
Growth retardation and changes in lung structure were noted at term after exposure of fetal monkeys to high dose glucocorticoids given at mid-gestation. 11, 12 This resulted in smaller lungs that contained fewer alveoli at term. 11, 12 In preterm sheep, repeat courses of antenatal glucocorticoids have been associated with increased alveolar volume and decreased alveolar numerical density. 30 There are few randomized studies in humans reporting follow-up PFTs after a single course of AS therapy, [31] [32] [33] and ours is the first to report follow- Measurements of pulmonary function have been used to quantify the newborn infant's response to different therapeutic interventions including AS therapy. 13, 20, 21, 27 Studies in humans and animal models demonstrated improvements in respiratory compliance and lung volumes after dosing with AS. 17, 19, 34 A single course of AS given within 1 week of delivery significantly increases Crs and FRC about 50%. 1, 2, 19 We reported a significant increase in Crs (20-30%) within 72 h of birth and decreased oxygen need in newborns whose mothers were randomized to a rescue course of AS versus placebo. 13 We also recently reported that at the time of discharge from the Neonatal 41 may have improved our ability to detect a difference between the two groups of patients at follow-up. Care Units for their cooperation with the study. We also thank the parents and infants who participated in this study. The authors have no financial relationships relevant to this article to disclose.
